Non-fatal opioid-related overdoses among adolescents in Massachusetts 2012-2014.
Adolescents
Opioid use disorder
Overdose
Journal
Drug and alcohol dependence
ISSN: 1879-0046
Titre abrégé: Drug Alcohol Depend
Pays: Ireland
ID NLM: 7513587
Informations de publication
Date de publication:
01 01 2019
01 01 2019
Historique:
received:
14
07
2018
revised:
21
09
2018
accepted:
29
09
2018
pubmed:
6
11
2018
medline:
17
4
2019
entrez:
5
11
2018
Statut:
ppublish
Résumé
Opioid-related overdoses and deaths among adolescents in the United States continue to increase, but little is known about adolescents who experience opioid-related non-fatal overdose (NFOD). Our objective was to describe (1) the characteristics of adolescents aged 11-17 who experienced NFOD and (2) their receipt of medications for opioid use disorder (MOUD) in the 12 months following NFOD, compared with adults. We created a retrospective cohort using six Massachusetts state agency datasets linked at the individual level, with information on 98% of state residents. Individuals entered the cohort if they experienced NFOD between January 1, 2012 and December 31, 2014. We compared adolescents to adults experiencing NFOD, examining individual characteristics and receipt of medications for opioid use disorder (MOUD)-methadone, buprenorphine, or naltrexone. Among 22,506 individuals who experienced NFOD during the study period, 195 (0.9%) were aged 11-17. Fifty-two percent (102/195) of adolescents were female, whereas only 38% of adults were female (P < 0.001). In the year prior to NFOD, 11% (21/195) of adolescents received a prescription opioid, compared to 43% of adults (P < 0.001), and <5% (<10/195) received any MOUD compared to 23% of adults (P < 0.001). In the 12 months after NFOD, only 8% (15/195) of adolescents received MOUD, compared to 29% of adults. Among individuals experiencing NFOD, adolescents were more likely to be female and less likely to have been prescribed opioids in the year prior. Few adolescents received MOUD before or after NFOD. Non-fatal overdose is a missed opportunity for starting evidence-based treatment in adolescents.
Sections du résumé
BACKGROUND
Opioid-related overdoses and deaths among adolescents in the United States continue to increase, but little is known about adolescents who experience opioid-related non-fatal overdose (NFOD). Our objective was to describe (1) the characteristics of adolescents aged 11-17 who experienced NFOD and (2) their receipt of medications for opioid use disorder (MOUD) in the 12 months following NFOD, compared with adults.
METHODS
We created a retrospective cohort using six Massachusetts state agency datasets linked at the individual level, with information on 98% of state residents. Individuals entered the cohort if they experienced NFOD between January 1, 2012 and December 31, 2014. We compared adolescents to adults experiencing NFOD, examining individual characteristics and receipt of medications for opioid use disorder (MOUD)-methadone, buprenorphine, or naltrexone.
RESULTS
Among 22,506 individuals who experienced NFOD during the study period, 195 (0.9%) were aged 11-17. Fifty-two percent (102/195) of adolescents were female, whereas only 38% of adults were female (P < 0.001). In the year prior to NFOD, 11% (21/195) of adolescents received a prescription opioid, compared to 43% of adults (P < 0.001), and <5% (<10/195) received any MOUD compared to 23% of adults (P < 0.001). In the 12 months after NFOD, only 8% (15/195) of adolescents received MOUD, compared to 29% of adults.
CONCLUSION
Among individuals experiencing NFOD, adolescents were more likely to be female and less likely to have been prescribed opioids in the year prior. Few adolescents received MOUD before or after NFOD. Non-fatal overdose is a missed opportunity for starting evidence-based treatment in adolescents.
Identifiants
pubmed: 30391835
pii: S0376-8716(18)30760-9
doi: 10.1016/j.drugalcdep.2018.09.020
pmc: PMC6312455
mid: NIHMS1510748
pii:
doi:
Substances chimiques
Analgesics, Opioid
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
28-31Subventions
Organisme : NIDA NIH HHS
ID : K23 DA044324
Pays : United States
Organisme : NIDA NIH HHS
ID : L40 DA042434
Pays : United States
Organisme : NIDA NIH HHS
ID : L30 DA044647
Pays : United States
Organisme : NCIPC CDC HHS
ID : U01 CE002780
Pays : United States
Organisme : NIDA NIH HHS
ID : K23 DA045085
Pays : United States
Organisme : NIDA NIH HHS
ID : K23 DA042168
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001430
Pays : United States
Informations de copyright
Copyright © 2018 Elsevier B.V. All rights reserved.
Références
Hum Organ. 2004 Sep;63(3):253-264
pubmed: 16685288
MMWR Morb Mortal Wkly Rep. 2018 Aug 10;67(31):845-849
pubmed: 30091969
MMWR Morb Mortal Wkly Rep. 2017 May 12;66(18):470-473
pubmed: 28493860
Pediatrics. 2016 Sep;138(3):
pubmed: 27550978
JAMA Pediatr. 2018 Nov 1;172(11):1029-1037
pubmed: 30208470
Pain Med. 2014 Oct;15(10):1765-70
pubmed: 25139712
MMWR Morb Mortal Wkly Rep. 2017 Apr 14;66(14):382-386
pubmed: 28406883
Pharmacoepidemiol Drug Saf. 2017 May;26(5):509-517
pubmed: 28074520
N Engl J Med. 2015 May 28;372(22):2118-26
pubmed: 25913111
J Adolesc Health. 2017 Jun;60(6):747-750
pubmed: 28258807
J Addict Med. 2017 Nov/Dec;11(6):415-416
pubmed: 28767537
Ann Intern Med. 2016 Jan 5;164(1):1-9
pubmed: 26720742
NCHS Data Brief. 2017 Aug;(282):1-8
pubmed: 29155681
Addict Behav. 2017 Nov;74:63-66
pubmed: 28582659
JAMA Pediatr. 2017 Aug 1;171(8):747-755
pubmed: 28628701
J Gen Intern Med. 2007 Sep;22(9):1268-73
pubmed: 17641933
Ann Intern Med. 2018 Aug 7;169(3):137-145
pubmed: 29913516